Articles tagged with Immunotherapy
Researchers at Edith Cowan University have found a genetic link between human leukocyte antigens and immunotherapy side effects in non-small cell lung cancer patients. The discovery enables doctors to tailor treatment to individual patients, reducing the risk of toxicities and improving overall outcomes.
Researchers at Cleveland Clinic discovered that pathogenic POLE/POLD1 genetic mutations in tumors lead to a high level of immune cell infiltration and improved response to immune checkpoint blockade therapy. The study's findings contribute to the growing list of discoveries that prove certain classes of drugs are more effective based o...
Researchers found specific T-cell populations expanded after immune therapy treatment, predicting which patients would respond best to the treatment. These biomarkers could help select patients for future trials to improve outcomes.
Researchers developed a two-step approach using whole exome sequencing to predict which patients respond to cancer immunotherapy. The study identified six genes, including KRAS and BRAF, that are enriched in patients who responded to treatment.
This volume of Oncotarget features groundbreaking research on various cancers, including breast, lung, colorectal, and neuroblastoma, as well as novel drug targets for bladder cancer. The studies also delve into the role of BRCA in breast and colorectal cancers.
Researchers have developed a way to fine-tune CAR T cell therapy to strike a balance between safety and efficacy, reducing the risk of severe side-effects. The new approach enables customisation of potency levels for individual patients, broadening its potential as a first-line treatment.
Researchers discovered that the TCF-1 protein enables plasticity in cells across neighborhoods during T cell development, weakening insulation and increasing interactions between adjacent neighborhoods. This finding sheds new light on immunotherapy approaches and could lead to more efficient cancer treatments.
A new study published in the Journal of Allergy and Clinical Immunology: In Practice found that infants under 12 months who undergo oral immunotherapy have a better safety profile compared to older preschoolers. The treatment, which involves gradually increasing exposure to peanut flour, is highly effective and safe for this age group.
Researchers at the University of Birmingham have identified a 'cellular brake' protein that may help prevent autoimmune responses in lung cancer patients undergoing immunotherapy treatment. This finding could enable clinicians to closely monitor high-risk patients and develop preventative strategies.
Scientists at Max Delbrück Center identify EBAG9 gene as key inhibitor of T cell function against tumors, releasing the brake and boosting immune response. The discovery aims to develop CAR T cells without EBAG9 for more effective leukemia treatments.
Researchers found that 'killer' T-cells used in immunotherapy can also destroy tumour lymphatic vessels, greatly reducing the risk of metastasis. This synergistic effect could increase treatment effectiveness against cancers with high lymphangiogenesis.
A new study found significant racial disparities in receiving immunotherapy for advanced liver cancer, with Black and Hispanic patients having lower access to the treatment. The analysis showed that immunotherapy was more effective than chemotherapy in improving survival rates.
Researchers at NUS Yong Loo Lin School of Medicine and Xiamen University have developed a novel nanovaccine that achieves complete clearance of solid tumors and induces long-lasting immune memory. The vaccine stimulates anti-tumor immunity by presenting antigens in a way that traditional vaccines cannot.
Researchers at MD Anderson Cancer Center found distinct gut microbiome signatures associated with immunotherapy response in patients with newly diagnosed glioblastoma. The study identified a link between gut microbiome signatures and immune checkpoint blockade response in melanoma, NSCLC, and sarcoma.
A recent study published in the New England Journal of Medicine found that dostarlimab was effective in treating a subtype of rectal cancer, showing remarkable responses and resolving difficult symptoms. The treatment offers a more effective and less toxic alternative to traditional chemotherapy and radiation.
A Phase II study found that immunotherapy before surgery improved median progression-free survival and overall survival for undifferentiated pleomorphic sarcoma and recurrent dedifferentiated liposarcoma patients. The treatment also showed an association between intratumoral B-cell receptor repertoire and survival.
A Phase 3 clinical trial is investigating the effectiveness of a combination of two immunotherapy drugs, nemvaluekin alfa and pembrolizumab, compared to standard chemotherapy for patients with platinum-resistant ovarian cancer. The trial aims to provide a novel treatment option with better efficacy and safety profiles.
Researchers at Massachusetts General Hospital discovered a novel immunotherapy mechanism that uses CD4+ T helper 2 cells to suppress breast cancer development. These cells force breast cancer cells to revert to benign breast gland cells, providing new insights into the treatment of this disease.
A Phase II clinical trial found that an immunotherapy drug combination extended the lives of patients with non-small cell lung cancer, improving survival by 14.5 months compared to standard care therapy. The treatment also reduced chemotherapy use and side effects.
Researchers validated a liquid biopsy test as a better predictor of immunotherapy response in lung cancer patients compared to traditional tumor biopsies. The test measures the PD-L1 biomarker in blood, showing improved accuracy in predicting treatment outcomes and survival.
Researchers at Washington State University have discovered that a specific population of CD4-positive helper T cells initiates antitumor immunity defenses, which can enhance the effectiveness of killer cell attacks on cancer cells. This finding holds promise for improving cancer immunotherapy response rates.
Researchers from CiQUS and Karolinska Institutet develop a new immunotherapeutic approach against cancer by blocking adenosine A2B receptors. The study demonstrates that this blockade reactivates the immune system, restoring its effectiveness against tumors.
MD Anderson research highlights new treatments for skin cancers, including novel therapies. The institution also showcased improved goals of care programs, which demonstrated significant reductions in ICU mortality and improved patient outcomes during the COVID-19 pandemic.
Researchers found that neoadjuvant immunotherapy with pembrolizumab significantly shrunk tumors in patients with desmoplastic melanoma, potentially allowing for less extensive surgery and radiation. The study showed a high response rate to treatment, with over half of patients achieving a pathologic complete response.
Scientists have discovered a small molecule that bypasses ADAR1 suppression and directly activates tumor cell death by ZBP1, inducing highly immunogenic cell death and destroying fibroblasts supporting tumor growth. This approach has the potential to improve the effectiveness of immunotherapy in treating therapy-resistant tumors.
Australian researchers have discovered specific gene networks rewired to drive peanut allergy remission through a combination treatment of probiotic and oral immunotherapy. This network reprogramming shuts down the allergic immune response responsible for causing food allergies.
Researchers at Massachusetts General Hospital developed two approaches to repair tumor blood vessels, alleviating hypoxia and improving chemotherapy's effectiveness. Combining these approaches may create a more powerful anti-cancer strategy.
A clinical trial found that adding immunotherapy to standard treatment increased the likelihood of complete tumor eradication in patients with high PD-L1 expression. The combination could become a new standard of care if confirmed in larger trials.
The new center aims to advance a groundbreaking combination of focused ultrasound and cancer immunotherapy, potentially revolutionizing cancer treatment. The partnership will focus on overcoming existing limitations of immunotherapy and expanding treatment options for various types of cancer.
Researchers discovered that memory B cells produce non-specific antibodies to combat virus mutants, working alongside phagocytes to screen for variants. This mechanism may offer protection against SARS-CoV2 and HIV variants, and could influence vaccine development.
A new study by Weill Cornell Medicine investigators found that T cells' genetic program and developmental path affect their response to immunotherapy. The results suggest that infiltrating T cells don't all meet the same fate in every tumor, with long-lived memory programs correlating strongly with overall survival
Researchers at University of Texas M.D. Anderson Cancer Center identify IL-6 as a key player in immunotherapy toxicity. A novel strategy combining IL-6 blockade with immune checkpoint blockade shows promise in reducing autoimmune side effects while preserving antitumor efficacy.
Researchers at Ochsner Health and MD Anderson have discovered that blocking interleukin-6 (IL-6) in lab models improves cancer responses while minimizing inflammation in healthy tissue. By targeting this cytokine, immune checkpoint inhibitors may become more targeted on tumors with fewer side effects.
Researchers at Sloan Kettering Institute have identified a new potential 'soldier' for cancer immunotherapy, killer innate-like T cells. These cells recognize unmutated antigens and can penetrate deeper into tissues where cancer is hiding, making them attractive as a target for immunotherapy.
Researchers at the University of Oklahoma are testing a novel therapy that combines local laser ablation and immunostimulants to treat metastatic pancreatic cancer. The treatment aims to stimulate the immune system to fight cancer cells, with promising preliminary results in pre-clinical studies and clinical trials.
Researchers discovered that checkpoint inhibitors can activate regulatory T cells, which can counteract the immune response. Blocking PD-L1 enhanced effector Treg activity, reducing ability to control parasite infections. This finding highlights complexity of immune system's balance between controlling pathogens and protecting healthy ...
Researchers have shed light on how immune checkpoint protein LAG3 modulates T cell activity, providing crucial information for the development of new LAG3-blocking therapies. The study found that LAG3 suppresses T cell activation by disrupting coreceptor-Lck association, even in the absence of MHC Class II molecules.
Researchers at Gladstone Institutes and UC San Francisco have developed a comprehensive rule book for designing therapeutic cells with improved specificity and safety. The new receptor system, dubbed SNIPRs, is small enough for cost-effective engineering into human cells and can detect and respond to even small amounts of its target. T...
Researchers found that vitamin E boosts immunotherapy responses by stimulating dendritic cell activity, leading to improved antigen presentation and enhanced antitumor immunity. Vitamin E treatment also showed promise in combining with cancer vaccines and immunogenic chemotherapies.
Researchers at Moffitt Cancer Center have discovered that tissue-resident memory T cells are crucial for recognizing tumor cells in ovarian cancer. These T cells arise from circulating T cells and undergo a differentiation process to target cancer cells, providing a potential roadmap for improved immunotherapy options.
Researchers load CAR-T cells with an oncolytic virus to target and kill solid cancer tumors, providing a potent immune response. The combination approach overcomes challenges in treating solid tumors with CAR-T cell therapy alone.
A new peptide-based vaccine, CoVac-1, has been shown to induce a T cell-dependent response in 93% of patients with B-cell deficiencies, including those with leukemia and lymphoma. The vaccine's T cell immunity exceeds that of individuals without immune deficiency or those who have received standard COVID-19 vaccines.
Researchers found that combining durvalumab with novel agents like oleclumab and monalizumab increased major pathological response rates compared to solo durvalumab. The study also identified key immune cell signatures associated with treatment outcomes.
Adding immunotherapy to chemotherapy before surgery reduced the risk of recurrence and death in lung cancer patients by 37%, according to a phase III trial. The treatment also led to a nearly twelvefold increase in pathological complete response, with 24% of patients achieving no active cancer remaining when the tumor was removed.
Researchers identified a genetic variant associated with increased response to anti-PD-1 therapy and higher immune-related side effects in lung cancer patients. The variant, found in 15.7% of exceptional responders, may be used to identify patients who would benefit from treatment.
Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.
Dr. Philip D. Greenberg has been elected as the American Association for Cancer Research President-Elect for 2022-2023. He will work to harness advances in cancer research and translate them for patient benefit, with a focus on addressing disparities in minority engagement.
A new study found that omega-3 fatty acid supplementation can broadly improve immunotherapy and other anti-cancer drugs in the clinical setting. In mice, diets enriched with omega-3s blocked tumor growth when combined with immunotherapy or anti-inflammatory treatment, indicating possible synergistic anti-tumor activity.
Researchers at Penn Medicine have developed a new approach to alter immune cells for CAR T cell therapy in just 24 hours, cutting manufacturing time from nine to 14 days. This could make the therapy more cost-effective and accessible to more patients.
A new therapy combination of immunotherapy, chemotherapy and an anti-inflammatory drug may improve immune response in patients with muscle-invasive bladder cancer. The treatment activates cells to fight tumor growth, potentially leading to better outcomes for patients who don't respond to current treatments.
Researchers at Ben-Gurion University have developed a potential treatment combination for advanced head and neck cancer, which shows promise in pre-clinical models. The therapy involves blocking a specific signaling pathway and sensitizing tumors to immunotherapy, resulting in the disappearance of tumors.
The Experimental Biology (EB) 2022 meeting features live presentations and a moderated Q&A session on groundbreaking studies. The virtual press conference reveals potential treatments for Parkinson's disease, COVID-19 vaccine-associated side effects, and alleviating food allergies.
Researchers at Penn Medicine have discovered a new approach to treat solid cancers using CDH17CAR T cells, which selectively target and eliminate gastrointestinal (GI) solid tumors like gastric, pancreatic, and colorectal cancers in preclinical models. Unlike other immunotherapies, CDH17CAR T cells do not show toxicity to healthy tissues.
In an animal study, researchers created an implantable biotechnology called MASTER that produces and releases CAR-T cells for attacking cancerous tumors. This technology reduces the manufacturing time from weeks to hours, increasing efficiency and effectiveness.
The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.
Dr. Steven A. Rosenberg's pioneering work on IL-2 and its use in treating metastatic melanoma and other cancers led to the FDA approval of first U.S.-born cancer immunotherapy. His subsequent research on CAR T-cell therapy has resulted in promising clinical results for various types of cancer.
Scientists at Albert Einstein College of Medicine have developed a novel therapeutic strategy that uses bacteria to deliver tetanus toxin into pancreatic tumor cells, inducing an immune response and killing the cancer. The treatment has shown promise in reducing cancer metastases by 87% and increasing mouse lifespan by 40%.
Researchers found that adding atezolizumab to chemoradiation treatment was safe and demonstrated immune activation in women with node-positive, locally advanced cervical cancer. The study also showed increased peripheral blood T-cell receptor clonal expansion and tumor-associated T-cell clones.
Researchers have discovered an essential role of LCOR in enabling cancer cells to present tumour antigens, making them visible to the immune system. This approach increases the success of immunotherapy in triple-negative breast cancer, a subtype with low treatment response rates.
Scientists have developed a genetic screening platform to identify genes that enhance immune cells' persistence and ability to eradicate tumor cells. By combining these genes with existing CAR-T cell therapy, researchers were able to engineer T cells that are more effective at eliminating tumor cells.